Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)

NCT00907478 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00907478
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00907478 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase IV, Open-Label, Multi-Center Study Evaluating Changes in Bone Marrow Morphology in Adult Subjects Receiving Romiplostim for the Treatment of Thrombocytopenia Associated With Immune (Idiopathic) Thrombocytopenia Purpura (ITP)
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
August 11, 2009
Completion date
January 14, 2014
Enrollment
169 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic thrombocytopenic purpura, thrombocytopenia